Regeneron Pharma (REGN) PT Raised to $790 at Truist Securities; High-Dose Eylea Data Removes Key Overhang
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas raised the price target on Regeneron Pharma (NASDAQ: REGN) to $790.00 (from $718.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
